Ser_BLC was overexpressed in HER2+ tumors vs. HR+ tumors (p  =  0.012) and over-expressed in HER2+ BC vs. TNBC (p  =  0.018) (Figure 3C). This evidence concerns the gene ERBB2 and breast cancer.